Blueberry Therapeutics is a pharmaceutical company focused on the discovery, development and commercialisation of high value medicines for the treatment of common dermatological conditions. It applies innovative technologies to improve the delivery of existing drugs through the skin and nail. This enables better efficacy, safety and patient compliance while reducing drug dosage and cost of goods. The company has a de-risked portfolio of best-in-class clinical and preclinical assets addressing high value and poorly served indications in dermatology. For more information about Blueberry Therapeutics, please visit www.blueberrytherapeutics.com.
BB2603 is a novel cutaneous spray of terbinafine hydrochloride with nanotechnology, which is designed to greatly enhance delivery of terbinafine to target fungal infections under the nail. Terbinafine has a wide range of antifungal activity against pathogenic fungi of skin, hair and nails, and is recommended for the treatment of onychomycosis and tinea pedis by both the Chinese and foreign guidelines.
Onychomycosis and tinea pedis are very common diseases in China. The incidence of onychomycosis accounts for 2%-18% of the population, while the incidence of tinea pedis accounts for approximately 15%, even up to 30%-70% of the population, characterized by high incidence and recurrence rate.
